Coya Therapeutics, Inc. (COYA)
COYA moved a median of +0.15% 30 minutes after news, and -0.48% by the close. How COYA actually reacts to news — the realized, point-in-time move the market made, measured across 247 labeled events over the last three years with zero look-ahead.
COYA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 231 |
| 30-min | +0.15% | 52% | 241 |
| 60-min | -0.67% | 45% | 247 |
| to close | -0.48% | 43% | 242 |
| Middle 50% of COYA reactions | -1.55% to +1.94% |
|---|---|
| Median reaction (30-min) | +0.15% |
| Measured reactions | 247 |
Half of all Coya Therapeutics, Inc. news events land between -1.55% and +1.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How COYA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 17 | -0.83% | 18% | -1.88% |
| Rating reiterations | 100 | 0.00% | 47% | -0.58% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how COYA ranks against every other measured name →
That’s how COYA usually reacts — get an email when it moves on news →Email me when COYA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to COYA's baseline. Nothing else.
Recent COYA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS | Press release | Business Wire | +0.22% | -6.70% | |
| Form 8-K Coya Therapeutics, Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | +0.22% | -6.70% | |
| Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference | Press release | Business Wire | -0.52% | -6.96% | |
| Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS | Press release | Business Wire | +0.82% | +0.00% | |
| Form 8-K Coya Therapeutics, Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +0.82% | +0.00% | |
| Coya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS | Press release | Business Wire | +0.43% | +0.65% | |
| Form 8-K Coya Therapeutics, Inc. For: Sep 15 | SEC filing · Form 8-K | SEC EDGAR | +0.43% | +0.65% | |
| Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation | Press release | Business Wire | -2.08% | -4.36% | |
| Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | Press release | Business Wire | +0.76% | +3.90% | |
| Form 10-Q Coya Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.76% | +3.90% | |
| Form 8-K Coya Therapeutics, Inc. For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +3.90% | |
| Form 8-K/A Coya Therapeutics, Inc. For: Mar 29 | SEC filing · Form 8-K | SEC EDGAR | -1.71% | — | |
| Form 8-K Coya Therapeutics, Inc. For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | -3.85% | +5.77% | |
| Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting | Press release | Business Wire | +0.00% | -3.34% | |
| Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease | Press release | Business Wire | +0.14% | +2.09% | |
| Coya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension Phase | Press release | Business Wire | -1.77% | +0.89% | |
| Coya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development Summit | Press release | Business Wire | -0.11% | +1.06% | |
| Form ARS Coya Therapeutics, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +8.10% | |
| Form DEF 14A Coya Therapeutics, Inc. For: Jun 25 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +8.10% | |
| Form DEFA14A Coya Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +8.10% | |
| Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Press release | Business Wire | +0.24% | +2.88% | |
| Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | Business Wire | +0.24% | +2.88% | |
| Form 10-Q Coya Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.24% | +2.88% | |
| Form 8-K Coya Therapeutics, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.24% | +2.88% | |
| Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS | Press release | Business Wire | +0.12% | +9.42% | |
| Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director | Press release | Business Wire | +0.76% | +1.26% | |
| Form 8-K Coya Therapeutics, Inc. For: Mar 29 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | +1.26% | |
| ReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COO | Press release | Business Wire | +0.24% | -1.43% | |
| Form EFFECT Coya Therapeutics, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.83% | -0.24% | |
| Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy | Press release | Business Wire | -0.45% | +0.45% | |
| Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results | Press release | Business Wire | +1.21% | +0.90% | |
| Form 10-K Coya Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.21% | +0.90% | |
| Form 8-K Coya Therapeutics, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +1.21% | +0.90% | |
| Form S-3 Coya Therapeutics, Inc. | SEC filing · Form S-3 | SEC EDGAR | +1.21% | +0.90% | |
| Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial | Press release | Business Wire | -0.82% | +1.43% | |
| Coya Therapeutics Announces $11.1 Million Private Placement | Press release | Business Wire | +3.41% | +2.20% | |
| Form 8-K Coya Therapeutics, Inc. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +3.41% | +2.20% | |
| Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders | Press release | Business Wire | -2.63% | +6.41% | |
| Form 8-K Coya Therapeutics, Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -2.63% | +6.41% | |
| Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients | Press release | Business Wire | +3.50% | -0.58% | |
| Form 8-K Coya Therapeutics, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +3.50% | -0.58% | |
| Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) | Press release | Business Wire | +1.56% | -6.78% | |
| Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | Press release | Business Wire | -2.54% | -5.27% | |
| Form 8-K Coya Therapeutics, Inc. For: Dec 16 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | -4.92% | |
| Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS | Press release | Business Wire | +1.49% | -0.16% | |
| Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences | Press release | Business Wire | +0.25% | -0.33% | |
| ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman | Press release | Business Wire | +0.25% | -0.33% | |
| Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update | Press release | Business Wire | +0.17% | +0.83% | |
| Form 10-Q Coya Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.17% | +0.83% | |
| Form 8-K Coya Therapeutics, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.17% | +0.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the COYA section they belong to.
Where else COYA is measured.
COYA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Coya Therapeutics, Inc.'s median reaction calculated?
Every labeled COYA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 247 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of COYA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does COYA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.